Revised age estimates for the primate-bearing localities of the Jebel Qatrani Formation (Fayum area, northern Egypt) have provided a new perspective on primate response to early Oligocene climate change in North Africa. Environmental changes associated with early Oligocene cooling might have driven the local extinction of at least 4 strepsirrhine primate clades (adapids, djebelemurines, plesiopithecids and galagids). Contrary to previous suggestions, oligopithecid (and possibly proteopithecid) anthropoids persisted beyond the Eocene-Oligocene boundary (EOB) in the Fayum area, and the former group evidently continued to diversify through the early Oligocene at lower latitudes. Propliopithecids and parapithecine parapithecids first appear in the Jebel Qatrani Formation millions of years after the EOB, so their derived dental and gnathic features can no longer be interpreted as sudden adaptive morphological responses to earliest Oligocene climatic events. Evidence for latitudinal contraction of Afro-Arabian primate distribution through the early Oligocene suggests that the profound late Oligocene restructuring of Afro-Arabian primate communities is most likely to have occurred in equatorial and low-latitude tropical Africa.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.